GUIDELINES ON THERAPEUTIC PRODUCTS TO TREAT HAEMOPHILIA AND OTHER HEREDITARY COAGULATION DISORDERS.

scientific article

GUIDELINES ON THERAPEUTIC PRODUCTS TO TREAT HAEMOPHILIA AND OTHER HEREDITARY COAGULATION DISORDERS. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1046/J.1365-2516.1997.00073.X
P698PubMed publication ID27214623

P2093author name stringUnited Kingdom Haemophilia Centre Directors Organisation Executive Committee
P433issue1
P407language of work or nameEnglishQ1860
P921main subjecthemophiliaQ134003
hemophilia AQ2092064
P304page(s)63-77
P577publication date1997-01-01
P1433published inHaemophiliaQ15753375
P1476titleGUIDELINES ON THERAPEUTIC PRODUCTS TO TREAT HAEMOPHILIA AND OTHER HEREDITARY COAGULATION DISORDERS.
P478volume3

Reverse relations

cites work (P2860)
Q33785738Audit of clinical management of von Willebrand disease during 1997 at a single institution and review of treatment patterns between 1980 and 1997.
Q41578620Batch recall of French plasma-derived products due to variant Creutzfeldt-Jakob disease risk: the psychological impact on haemophilic patients, changes in their therapeutic demands and behaviour and ethical considerations.
Q24684165C1 inhibitor deficiency: consensus document
Q36381542Clinical implications of emerging pathogens in haemophilia: the variant Creutzfeldt-Jakob disease experience
Q37619008Cost-effectiveness of prophylaxis against on-demand treatment in boys with severe hemophilia A in Iran
Q45888910Cost-utility analysis of primary prophylaxis versus treatment on-demand for individuals with severe haemophilia
Q38024851Dealing with the uncertain risk of variant Creutzfeldt-Jakob disease transmission by coagulation replacement products
Q45270351Effectiveness in controlling haemorrhage after dental scaling in people with haemophilia by using tranexamic acid mouthwash
Q45885096Experience of prophylaxis treatment in children with severe haemophilia
Q38165089Guidance on the dental management of patients with haemophilia and congenital bleeding disorders
Q33815761Guidelines on replacement therapy for haemophilia and inherited coagulation disorders in Italy
Q34229310Haemophilias: advances towards genetic engineering replacement therapy
Q45889715Hepatitis in haemophilia
Q43622975Management of von Willebrand disease: a survey on current clinical practice from the haemophilia centres of North America
Q45888311Neoantigens and antibodies to factor VIII.
Q45888117New-variant Creutzfeldt-Jakob disease and treatment of haemophilia. Executive Committee UK Haemophilia Directors' Organisation
Q45877518Potency estimation of recombinant factor VIII: effect of assay method and standard
Q38109706Purchasing factor concentrates in the 21st century through competitive tendering
Q41711748Recombinant coagulation factors
Q34202036Retrospective review of the management of elective surgery with desmopressin and clotting factor concentrates in patients with von Willebrand disease
Q39871501Risk reduction strategies for variant Creutzfeldt-Jakob disease transmission by UK plasma products and their impact on patients with inherited bleeding disorders
Q45873337Spontaneous intracranial bleeding in two patients with congenital afibrinogenaemia and the role of replacement therapy
Q34574267State of care for hemophilia in pediatric patients
Q45872630The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO).
Q45888459The effect of monoclonal or ion-exchange purified factor VIII concentrate on HIV disease progression: a prospective cohort comparison
Q37702839The evaluation of fibrin sealants and tissue adhesives in oral surgery among patients with bleeding disorders
Q45873704The responsibility of separating truth from myth to patient and family
Q45873317Unexpected presentation of type 2N von Willebrand disease in pregnancy
Q33992794Viral inactivation of fresh frozen plasma
Q47918948von Willebrand disease and its management in oral and maxillofacial surgery

Search more.